Vial Raises $67M in Series B Funding
Summary
The round was led by General Catalyst with participation from Byers Capital, and BoxGroup. The company intends to use the funds to accelerate the clinical development of medicines. Led by CEO Simon Burns, Vial is a tech-enabled CRO that aims to make efficient trials through its technology platform that powers trials end-to-end from site startup to database lock. The platform is made up of three key platforms: Site Startup platform, eSource platform and Patient Recruiting platform. The company operates across multiple therapeutic areas (Dermatology CRO, Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, Neurology CRO, and Cardiology CRO).
Funding
Amount
$67.0M
Total raised
Date
November 30, 2022
Announcement date
Investors
-
Lead investors
Company
http://www.vial.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected